179 related articles for article (PubMed ID: 16276468)
1. Management of von Willebrand disease in developing countries.
Mannucci PM
Semin Thromb Hemost; 2005 Nov; 31(5):602-9. PubMed ID: 16276468
[TBL] [Abstract][Full Text] [Related]
2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
4. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
5. Management of inherited von Willebrand disease in 2007.
Federici AB; Mannucci PM
Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
[TBL] [Abstract][Full Text] [Related]
6. Management of inherited von Willebrand disease in 2006.
Federici AB
Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.
Sánchez-Luceros A; Meschengieser SS; Woods AI; Chuit R; Turdó K; Blanco A; Lazzari MA
Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand's disease: clinical management.
Federici AB; Castaman G; Thompson A; Berntorp E
Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
[TBL] [Abstract][Full Text] [Related]
9. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
10. [Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports].
Kleinschmidt S; Fuchs-Buder T; Wilhelm W; Seyfert UT; Mörsdorf S
Anaesthesist; 2002 Oct; 51(10):825-34. PubMed ID: 12395174
[TBL] [Abstract][Full Text] [Related]
11. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
12. Mild forms of von Willebrand disease: diagnosis and management.
Federici AB
Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
[TBL] [Abstract][Full Text] [Related]
13. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
15. Therapy of von Willebrand disease.
Scott JP; Montgomery RR
Semin Thromb Hemost; 1993; 19(1):37-47. PubMed ID: 8456322
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
17. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
18. Treatment of urgent bleeding in von Willebrand disease.
Gill JC
Thromb Res; 2007; 120 Suppl 1():S21-5. PubMed ID: 17490729
[TBL] [Abstract][Full Text] [Related]
19. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Nitu-Whalley IC; Griffioen A; Harrington C; Lee CA
Am J Hematol; 2001 Apr; 66(4):280-4. PubMed ID: 11279640
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of von Willebrand disease in developing countries.
Srivastava A; Rodeghiero F
Semin Thromb Hemost; 2005 Nov; 31(5):569-76. PubMed ID: 16276466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
